Armas Pharmaceuticals is announcing the launch of their first injectable to the U.S. market, Azacitidine for Injection 100 MG. Azacitidine for Injection, a generic to Vidaza, is used for treating myelodysplastic syndrome, a form of cancer that leads to one or more blood cell types dropping to low numbers.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Azacitidine, an oncology injectable, has an approximate market size of $116 million annually. Armas expects to launch nine or more generic injectable and oral products through the 1st quarter of 2019, with a market size totaling more than $430 million annually.
"We are pleased to launch our first product in the U.S. market. This will be the first of a number of high-quality pharmaceutical products that we will launch in the Armas Pharmaceutical label through our partnerships. With Armas's strong customer base and our outstanding partners, I have no doubt that Armas Pharmaceuticals will bring exceptional value with our upcoming product launches to healthcare professionals," said John Niemi, President & CEO of Armas.